Acute Lymphoblastic Leukemia Webinar Archive
AALL1331 Blinatumomab in First Relapse of B Lineage Acute Lymphoblastic Leukemia
Obtaining Continuing Nursing Education (CNE)
Viewers are eligible to receive 1 CNE by listening to the program and successfully completing an online posttest and evaluation (free for members, $15 for non-members). Anyone that completes the entire webinar is eligible to receive contact hours.
We urge you to be aware of the continuing education requirements of your own state board of nursing, especially for those states in which continuing education is mandatory.
Current survival rates for most pediatric patients with a first relapse of acute lymphoblastic leukemia (ALL) are dismal. Treatment strategies for relapsed ALL include intensive chemotherapy often followed by hematopoietic stem cell transplant. Blinatumomab is a new targeted therapy that has shown promising clinical activity in early phase clinical trials in both adult and pediatric patients with relapsed ALL.
Blinatumomab is a bispecific T-cell engager linking CD19 positive B-cells, including ALL cells, with CD3 T-cells, inducing T-cell activation and apoptosis. Blinatumomab has a distinctive toxicity profile including cytokine release syndrome (CRS) and reversible neurotoxicity. The current COG AALL1331 study aims to determine if the addition of Blinatumomab will improve outcomes for pediatric patients with a first relapse of ALL. This session will review the COG AALL1331 protocol and will include discussion of Blinatumomab administration and highlight nursing care of patients enrolled on this trial.
Sue Zupanec, RN NP
The Hospital for Sick Children
Toronto, ON Canada
Debra Schissel, RN CPON®
Lead Nurse Research Coordinator
Children's Hospital Colorado
- Review the background of pediatric relapsed ALL, including, risk classification, survival rates, and the most promising clinical trial results to date.
- Describe the mechanism of action of Blinatumomab and review clinical activity and reported toxicity from early phase clinical trials both in adult and pediatric patients.
- Review the COG AALL1331 protocol and the nursing considerations important for Blinatumomab administration and for the provision of nursing care for patients receiving this new targeted agent.
Identified Learning Gaps
As a result of attending this activity, the learner will be able to demonstrate an increase knowledge base in:
- New and innovative therapies in hematology, oncology and hematopoietic progenitor cell transplant.
Current trends in hematology/oncology and hematopoietic progenitor cell transplant.
- The learner will be able to identify innovative strategies essential for managing the challenges facing pediatric hematology/oncology nurses and the patients we serve.
- The learner will demonstrate increased knowledge related to the care of children, adolescents and young adults with hematologic or oncologic disorders.
The measurement of these outcomes will be evidenced by evaluations and post testing.
APHON would like to thank our educational grantor for their support:
Accreditation and Disclaimers
Individual Learning Needs Assessment (ILNA) Coding
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.
CPHON® Blueprint: Treatment
BMTCN® Blueprint: Professional
ONCC review is only for designating content to be used for recertification points and is not for CNE accreditation. CNE programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the CNE provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program. Have questions regarding the CPHON® ILNA Coding? Please visit the ONCC website or call them toll-free at 877.769.ONCC (US and Canada only).
The Association of Pediatric Hematology/Oncology Nurses (APHON) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
This session is eligible for 0.25 pharmacology contact hours.
Faculty Disclosure of Relevant Financial Relationship(s)
A staff member, volunteer (faculty), or their family member who has an affiliation with a commercial company must declare that relationship in advance of involvement with an education activity that could be used as a forum to promote the interest of that company and its products. The material presented in this activity represents the opinion of the presenters and not necessarily the views of APHON.
Faculty and nurse planners report no conflict of interest with the content of this activity.
No off-label use was discussed.